Contents

Introduction 11

Aims and outline 37

Part I Immunogenetics of urogenital tract mucosa and Chlamydia trachomatis infections

Chapter 1 47
Epidemiology, diagnostics and treatment of urogenital Chlamydia trachomatis infections
Karimi O et al.
Tijdschr Infect 2010;5:208-214

Chapter 2 65
Chlamydia trachomatis: identification of susceptibility markers for ocular and sexually transmitted infection by immunogenetics
Morré SA, Karimi O et al.

Chapter 3 95
TLR2 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women
Karimi O et al.
Drugs of Today 2009,45(Suppl.B):67-74

Chapter 4 109
TLR2, TLR4, and TLR9 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women
Karimi O et al. submitted

Chapter 5 127
CXCR5 regulates Chlamydia tubal pathology in mice and humans
Karimi O et al. submitted
Part II  Immunogenetics of Inflammatory Bowel Disease

Chapter 6  167
JAK2 V617F mutation is not involved in thromboembolism in IBD
Karimi O et al.
Inflamm Bowel Dis 2008;14:1606–1607 (Letters to Editor)

Chapter 7  173
Functional polymorphisms in the blood coagulation factor F13A1 gene and inflammatory bowel disease in the Netherlands
Karimi O et al. submitted

Chapter 8  191
Distribution of peroxisome proliferator-activated receptor-γ polymorphisms in Chinese and Dutch patients with inflammatory bowel disease
Shrestha U, Karimi O et al.
Inflamm Bowel Dis 2010;16:312–319

Chapter 9  207
A new avenue to investigate: the autophagic process. From Crohn’s disease to Chlamydia
Peña AS, Karimi O, Crusius JBA
Drugs of Today 2009;45(Suppl. B):113-117
Part III Immunomodulation by probiotics

Chapter 10 221
Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn’s disease: a pilot study
Karimi O et al.
Drugs of Today 2005,41(7):453-459

Chapter 11 233
Probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease

A compilation of

Indications and challenges of probiotics, prebiotics and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease
Karimi O, Peña AS
J Clin Gastroenterol 2008;42:S136–S141

and

Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary
Karimi O, Peña AS
Esp Enferm Dig(Madrid) 2005;97:570-574

Chapter 12 249
Probiotics in clinical practice as therapeutics against enteric disorders
Karimi O, Peña AS
Chapter 15 in Probiotic Bacteria and Enteric Infections.
Cytoprotection by Probiotic Bacteria.
Eds JJ Malago, R Marinsek-Logar and JFJG Koninkx
General discussion, summary and future perspectives  273
Samenvatting  301

Addendum
  Publications  315
  Dankwoord  317
  Authors and affiliations  321
  Curriculum vitae  327